A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
Conditions
Solid Tumor
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
National GCP Center for Anticancer Drugs,The Independent Ethics Committee, Beijing, Beijing Municipality, China
The Cancer Hospital of the Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China
Hunan Cancer Hospital, Hunan, Changsha, China
Fujian Cancer Hospital, Fuzhou, Fujian, China
Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China
Yuebei People's Hospital, Shaoguan, Guangdong, China
The First Affiliated Hospital of Guilin Medical Universty, Guilin, Guangxi, China
Liuzhou Workers' Hospital, Liuzhou, Guangxi, China
The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
Henan Cancer Hospital, Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an, Shanxi, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
SIR RUN RUN SHAW Hospital Zhejiang University School Of Medicine, Hangzhou, Zhejiang, China
Study leads
Jing wang
Principal Investigator
Hunan Cancer Hospital
LingYIng Wu
Principal Investigator
The Cancer Hospital of the Chinese Academy of Medical Sciences